Review

Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis

Juan JIN, Yan CHANG, Wei WEI*

Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Antiinflammatory and Immunopharmacology of the Education Ministry of China, Hefei 230032, China

Rheumatoid arthritis (RA) is a chronic progressive autoimmune disease that dramatically impairs quality of life. A number of compounds are available to treat RA, but they vary in effectiveness. Thus, no optimal treatment strategy has been defined. Currently, disease-modifying anti-rheumatic drugs (DMARDs) and anti-tumor necrosis factor-alpha (anti-TNF-α) agents are considered the treatments of choice. For patients with inadequate responses to DMARD therapy, one recommended therapeutic alternative is anti-TNF-α therapy. Anti-TNF-α agents are effective and have rapid onset of action compared with DMARDs. Elucidating the differences in effectiveness of anti-TNF-α compounds has important clinical implications. By comparing the efficacy, safety and use principle of different treatment options, this review focuses on providing important information about three anti-TNF-α compounds (etanercept, infliximab, and adalimumab) to help define optimal treatments for RA patients.

Keywords: rheumatoid arthritis; anti-tumor necrosis factor-alpha; etanercept; infliximab; adalimumab; methotrexate

Acta Pharmacologica Sinica (2010) 31: 1133–1140; doi: 10.1038/aps.2010.134; published online 16 Aug 2010

Introduction

Rheumatoid arthritis (RA) is a chronic progressive autoimmune disease that is related to erosion of articular cartilage and subchondral bone, deformity, and impaired quality of life[1]. Disability and joint damage occur rapidly and early in the course of RA[1]. With the development of biologics, all of this can be achieved to some extent. Biologics such as interleukin 1 (IL-1) receptor antagonists (anakinra) and anti-tumor necrosis factor-α (anti-TNF-α) agents are typically used to treat RA, and adalimumab are generally well tolerated.

Among these biologics, TNF-α inhibitors have been used successfully to treat RA patients. Anti-TNF-α therapy leads to substantial functional improvement in the vast majority of patients and down-regulates inflammatory cytokines stimulated by TNF-α. The use of methotrexate (MTX) in combination with three such agents has dramatically improved the treatment of severe RA[2-4]. Studies have established that combination therapy can provide greater therapeutic benefits than single-drug regimens. Due to the safety and efficacy of combination therapy, various combination therapies are widely used in the treatment of RA patients. Clinical trials, however, indicate that a significant number of RA patients do not respond to these therapies. With the increased number of therapeutic options, the optimal therapeutic strategy for RA patients needs to be defined. This review describes the efficacy and safety of different anti-TNF-α-based therapies and investigates the optimal therapeutic strategy to help optimize everyday clinical practice. The American College of Rheumatology (ACR) efficacy response criteria is used to assess clinical response. This review analyzes the ACR response rates [20% (ACR20), 50% (ACR50), and 70% (ACR70), respectively] of different therapeutic strategies against RA.

The properties of three anti-TNF-α agents

TNF-α is a cytokine that plays an important role in joint inflammation. The effects of a TNF-α blockade are partially dependent on synovial TNF-α expression and infiltration by TNF-α-producing inflammatory cells[5]. Infliximab, etanercept and adalimumab have been available since 1999[6]. They bind and block TNF-α by different mechanisms, and etanercept additionally binds to lymphotoxin[7]. Despite their quite short histories, many studies have been published concerning these agents. Anti-TNF-α therapy leads to substantial functional improvement in the vast majority of patients and down-regulates inflammatory cytokines stimulated by TNF-α. The basic properties of infliximab, etanercept and adalimumab, which are typically used to treat RA, are briefly described in Table 1. The mechanisms of action, efficacy and safety of these com-
pounds have been demonstrated in clinical trials, which allow physicians to use them more effectively.

The efficacy, drug continuation rates and safety of infliximab have been assessed in trials\cite{2, 9–11}. The mechanism of action of infliximab is shown in Figure 1. Infliximab should be used in patients with active disease who have not responded adequately to at least two disease-modifying anti-rheumatic drugs (DMARDs) including MTX (unless contraindicated)\cite{12}. Frequently administered doses of infliximab may result in high peak serum concentrations\cite{9}. Patients receiving infliximab are more likely to discontinue therapy because of side effects, which are occasionally severe, as well as infections and infusion reactions\cite{8}. However, infliximab has been found to have a relatively acceptable toxicity profile\cite{3}. Characteristics of infliximab that may influence patient persistence include a preferred administration method and less frequent needle sticks compared with subcutaneous agents\cite{13}.

Treatment of RA with infliximab is thought to induce the humoral immune response against organ-specific or non-organ-specific antigens in RA patients\cite{10} and inhibit IL-1 and IL-6 gene expression in human osteoblastic cells\cite{14}. Anti-inflammatory therapy with infliximab improves HDL-cholesterol anti-oxidative capacity in RA patients\cite{2}. Research indicates that smoking has a negative effect on RA patients treated with infliximab\cite{30}. Analysis of whole blood gene expression profiles of RA patients can be used to build a robust predictor of the response to infliximab therapy, in which an eight-gene blood expression profile predicts the response to infliximab in RA patients. For example, a significantly higher number of CD4+CD25+ cells were found in the responder group compared to the non-responder group at baseline\cite{16}. Apolipoprotein A-1 was predictive of a good response to infliximab, whereas platelet factor 4 was associated with non-responders\cite{17}.

Adalimumab exerts its therapeutic effects by blocking the interaction of TNF-α with the p55 and p75 receptors\cite{18} and decreasing mean white blood cell counts, platelet counts, and neutrophil percentages\cite{4}. Responses to adalimumab are rapid, with 22.2% of patients achieving an ACR20 response within 24 hours\cite{19}. After 52 weeks of administration, patients did not develop new erosions and suffered lower rates of radiographic progression\cite{4}. Adalimumab is effective and well tolerated not only in RA patients that were previously treated with etanercept and/or infliximab\cite{20} but also in difficult-to-treat patients with active RA\cite{5}. Adalimumab is very effective at inhibiting the progression and reducing the signs and symptoms of structural joint damage. Adalimumab improves physical function in active RA patients who previously had an incomplete response to MTX\cite{4}. Patients receiving adalimumab are more likely to discontinue therapy because of side effects and injection reactions\cite{8}.

Etanercept, a fusion protein of the soluble TNF receptor and Fc portion of immunoglobulin, was marginally more effective than MTX in reducing the symptoms of RA\cite{23} but was no more effective than MTX for slowing the radiographic progression of joint destruction in a 1-year trial, as determined by the primary radiographic endpoint\cite{24}. However, for the second consecutive year, the situation was reversed\cite{8}. For patients with long disease durations and who are unresponsive to MTX

---

**Table 1.** Basic properties of infliximab, etanercept and adalimumab.

| Drug | Molecular structure | Dosage | Administration route | Adverse effects |
|------|---------------------|--------|----------------------|-----------------|
| INF  | Chimeric monoclonal antibody | 3 mg/kg/8 week administered at weeks 0, 2, 6, and 8 and every 8 weeks thereafter | Intravenous | Severe infection; injection site reaction; hypotension; headache |
| ADA  | Humanized monoclonal antibody | 40 mg every 2 weeks | Subcutaneous | Infection; tuberculosis, malignancy; serious infection; demyelinating disease, SLE |
| ETA  | Fusion protein of soluble TNF receptor and Fc portion of immunoglobulin | 25 mg twice a week | Subcutaneous | Nausea; abdominal; pain; injection reaction; headache; back pain; increased cough; vomiting; asthenia; arthralgia; hypertension; rash; diarrhea; pain |

INF: infliximab; ADA: adalimumab; ETA: etanercept

---

Figure 1. The mechanism and impact of infliximab.
treatment\cite{22} or not adequately responding to sulfasalazine\cite{22}, etanercept is a more effective alternative. The safety profile of etanercept is superior because of its limited range of doses\cite{8}. It is generally safe and well tolerated by elderly RA patients, and no serious risks have been reported for subjects aged ≥65 years\cite{23}. Elderly RA patients treated with etanercept experience significant improvements in disease activity and function without incurring additional safety concerns\cite{24}. Elderly RA patients treated with etanercept exhibit rapid improvements in functional status during controlled studies, and these improvements are sustained during open-label extension trials\cite{25}. Studies with RA patients showed that treatment with etanercept elicits a lower frequency of anti-etanercept antibodies\cite{26} compared with the frequency of anti-infliximab antibodies elicited by infliximab therapy\cite{27}. Patients receiving etanercept are less likely to discontinue because of side effects but are more likely to experience injection site reactions\cite{8}. With etanercept treatment, there are rarely life-threatening adverse events, but injection site reactions are quite common\cite{28, 29}.

Due to the different safety profiles of these three anti-TNF-α agents, some patients are forced to change therapeutic strategies. The safety profiles of the three agents are compared in Table 2, and the efficacy of the agents in terms of ACR20, ACR50, and ACR70 response rates are shown in Table 3.

**The evaluation of anti-TNF-α agents**

Perhaps because of differences in the sites of action and molecular structure of these three anti-TNF-α agents, individual patients have differential responses. RA patients who experience treatment failure with one anti-TNF-α agent, due to either inefficacy or toxicity, are frequently switched to a second anti-TNF-α agent to determine if the new agent is more effective. Many concerns have been raised about switching between anti-TNF-α agents. Researchers have found that patients who fail to respond to TNF-α antagonist therapy can be switched to another TNF-α antagonist with improved response rates\cite{35–37}. Infliximab is a possible alternative for patients who do not adequately respond to etanercept. Conversely, treatment with etanercept has similar clinical efficacy for patients who discontinued infliximab therapy due to adverse events\cite{30}. For these patients, etanercept maintains the clinical benefit achieved by infliximab\cite{30}. Etanercept provides a well-tolerated and effective treatment option for some patients even when infliximab therapy has been ineffective\cite{31}. Response rates of first-time anti-TNF-α switchers are somewhat below those of anti-TNF-α-naive RA patients, while the markedly inferior response rates of second-time switchers suggest other therapeutic options should be considered in this situation\cite{40}.

One study suggests that failure to respond to infliximab and etanercept may predict failure to respond to adalimumab\cite{41}. Some studies have investigated why certain RA patients fail to respond to anti-TNF agents and how antibodies against anti-TNF agents influence response after switching between anti-TNF agents. One study showed that patients who develop anti-infliximab antibodies are more likely to develop anti-adalimumab antibodies than anti-TNF-naive patients. It has been suggested that a second anti-TNF agent should be offered to RA patients who fail to respond to anti-TNF therapy in the

**Table 2.** Different continuation rates of infliximab, etanercept and adalimumab therapy.

| Drugs | Continuation rate (<year 1) | Continuation rate (year 2) | Persistence rate | Major reason of discontinuation |
|-------|---------------------------|---------------------------|-----------------|---------------------------------|
| INF   | 78.0% (284 days)\cite{30}  | Not available             | 78.0%\cite{30}  | Due to adverse events patients suffer severe side effects\cite{8} |
| ADA   | 70.8% (258 days)\cite{30}  | 60.9%\cite{31}            | 70.8%\cite{30}  | Due to adverse events patients suffer injection site reactions\cite{8} |
| ETA   | 72.8% (256 days)\cite{30}  | 61%\cite{33}              | 72.8%\cite{30}  | Due to lack of efficacy patients suffer injection site reactions\cite{8} |

INF: infliximab; ADA: adalimumab; ETA: etanercept

**Table 3.** Efficacy of infliximab, etanercept and adalimumab in terms of ACR20, ACR50, and ACR70 response rates.

| Groups | 3 mon ACR20 | 3 mon ACR50 | 3 mon ACR70 | 6 mon ACR20 | 6 mon ACR50 | 6 mon ACR70 | 12 mon ACR20 | 12 mon ACR50 | 12 mon ACR70 | 24 mon ACR20 | 24 mon ACR50 | 24 mon ACR70 |
|--------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| INF    | 60%\cite{20} | 33%         |             | 92%\cite{34} | 58%         | 16%         | 71%         | 42%         | 15%         | 83%         | 60%         | 19%         |
| ADA    |             |             |             | 63%\cite{20} |             |             | 54%\cite{31} | 41%         | 26%         | 49%         | 37%         | 28%         |
| ETA    | 78%\cite{33} | 46%         | 22%         | 77%         | 46%         | 26%         | 77%         | 47%         | 75%         | 54%         | 27%         |

Mon: month; INF: infliximab; ADA: adalimumab; ETA: etanercept
absence of anti-biological antibodies. Further investigation is needed to determine the efficacy of this therapeutic option.

**Therapeutic strategy of combination treatment with MTX**

TNF-α antagonists are generally effective in the treatment of RA. However, some RA patients do not respond or fail to maintain their clinical response over time. At present, many clinical trials have shown that combination therapies are effective in treating several inflammatory disorders. In patients who are naive to MTX or who have not previously failed MTX treatment, TNF blockade in combination with MTX is significantly more effective than MTX monotherapy against early RA. For patients with early or established RA, treatment with the combination of anti-TNF-α drugs and MTX has produced increased clinical remission rates associated with greater control of radiographic progression compared with traditional DMARD or MTX monotherapy.

**Infliximab plus methotrexate**

Accumulated evidence from controlled trials has demonstrated that combination treatment with infliximab and MTX is more effective than single-drug regimens. The ACR response rate is higher for infliximab combined with MTX than for MTX alone. Patients receiving the combination treatment show lower radiographic progression, higher remission rates and improved efficacy compared to patients receiving MTX alone. Infliximab plus MTX can produce a significantly higher number of responders. The combination treatment can inhibit radiographic progression across all disease activity states, irrespective of the levels of traditional predictors. It was found that patients with greater joint damage at baseline showed lower disease progression with infliximab plus MTX therapy compared with MTX monotherapy. RA patients who received initial combination therapy with infliximab have earlier functional improvement, slower progression of radiographic joint damage and fewer side effects than patients who received monotherapy. Even in patients without clinical improvement, treatment with infliximab plus MTX provided significant benefits against the destructive process. The use of infliximab along with optimal doses of MTX significantly retards the progression of radiographic changes in patients with persistently elevated disease activity. Studies with RA patients have shown that the prevalence of anti-infliximab antibodies increases over time, and this phenomenon can result in deceased infliximab effectiveness. However, the immunogenicity of infliximab can be significantly reduced in combination with MTX.

Some studies have shown that there is an increased risk of serious infections when infliximab is combined with MTX. Some researchers suggest that infliximab in combination with MTX should be limited to early RA patients with clinical and biological signs of aggressive disease, such as an insufficient response to MTX alone or the presence of rapidly progressing erosions.

**Adalimumab plus MTX**

After 12 months of therapy, more patients receiving combination therapy with adalimumab plus MTX exhibit an ACR50 response than patients receiving MTX or adalimumab alone (62% vs 46% and 41%, respectively). For patients with early aggressive RA, combination therapy is significantly superior to monotherapy in improving signs and symptoms of disease, inhibiting radiographic progression and promoting clinical remission. Patients receiving adalimumab plus MTX demonstrate significant and rapid improvement in disease activity compared with those receiving placebo plus MTX. Through 24 weeks of treatment, there were statistically significant decreases in serum levels of the cartilage destruction marker pro-matrix metalloproteinase (pro-MMP) compared to baseline with adalimumab plus MTX therapy.

**Etanercept plus MTX**

Benefits of combined use of etanercept with MTX have been demonstrated in several trials. Patients receiving either the combination of etanercept with MTX or etanercept monotherapy are more likely to achieve a mean ACR20 response at 12 months than patients receiving MTX monotherapy. This combination has greater effects on remission rates, deceased radiographic progression and greater improvement in disability than MTX monotherapy. Furthermore, this regimen provides the highest therapeutic effect in RA patients with moderate disease activity. For patients with active RA and intolerance or unsatisfactory response to MTX, combining etanercept with MTX is an effective way of reducing disability, pain, disease activity, and morning stiffness, and of improving general health. The combination of etanercept and MTX is significantly better at reducing disease activity, improving functional disability, and retarding radiographic progression than MTX or etanercept alone. In terms of safety profiles, the number of patients who withdrew from a study was significantly lower in the combination therapy group than in the MTX monotherapy group. In addition, combination treatment is more effective than etanercept alone or etanercept plus non-MTX, non-biologic DMARDs. There are large differences in the effectiveness of combination therapies with MTX, as shown in Table 4.

Patients receiving infliximab are more likely to require persistent therapy compared to patients receiving adalimumab or etanercept. The effects achieved with etanercept and adalimumab in patients with short-lasting, less severe disease are equivalent to those obtained with first-time MTX treatment. The effect of treatment with etanercept or adalimumab does not differ from that of treatment with MTX. There is high treatment persistence with all of the combination therapies, especially in patients treated with infliximab plus MTX, who had significantly higher persistence rates compared with those treated with adalimumab plus MTX or etanercept plus MTX. TNF-α antagonists in combination with MTX have proven superior to single-drug regimens and are now considered the most effective strategies for treating RA.
The application of other anti-TNF-α drugs

Golimumab

Golimumab is a human anti-TNF-α monoclonal antibody that is generated and affinity matured in an in vivo system. Golimumab has high affinity and specificity for human TNF-α and effectively neutralizes TNF-α bioactivity in vitro. Golimumab plus MTX effectively reduced the signs and symptoms of RA and is generally well tolerated in patients with inadequate responses to MTX[57]. Golimumab in combination with MTX in patients with active RA significantly reduced the signs and symptoms of RA and improved physical function[58]. The significant decreases in serum E-selectin, IL-18, serum amyloid A and MMP-9 levels associated with combination therapy with golimumab and MTX may be useful in predicting clinical response[59].

RA patients treated with 100 mg of golimumab and placebo capsules produced anti-golimumab antibodies. The study also shows that antinuclear antibodies are produced after treatment with golimumab (50 mg or 100 mg) combined with MTX[58]. The safety profile and tolerability of golimumab are consistent with those of other TNF-α inhibitors[60, 61], and unexpected adverse events or an increased frequency of specific adverse events are not observed[60].

Certolizumab pegol

Certolizumab pegol is a PEGylated Fab' fragment of a humanized monoclonal antibody that binds and neutralizes human TNF-α[62]. Certolizumab pegol is an example of a TNF inhibitor in which PEGylation could potentially optimize the delivery of the neutralizing moiety by specifically targeting the inflamed tissue in RA patients[63]. Certolizumab pegol does not induce apoptosis because certolizumab pegol binds to a different epitope than the other agents, which leads to a different signaling pattern inside cells[62]. Compared to placebo treatment, treatment with 400 mg of certolizumab pegol monotherapy every 4 weeks effectively reduced the signs and symptoms of active RA in patients that previously did not respond to DMARDs compared with placebo[64]. Most adverse events induced by treatment with certolizumab pegol are mild or moderate[64].

The effect of anti-TNF-α drugs on RA patients with concomitant disease

Patients with RA frequently have mood and anxiety disorders, and anti-TNF-α drugs may be useful for improving the mental status of these patients[65]. Anti-TNF-α therapy has been demonstrated to be effective, safe and well tolerated in the setting of hepatic C virus (HCV) infection[66]. Blocking TNF-α could play a protective role in the progression of HCV-related liver fibrosis[67]. Anti-TNF-α therapy combined with periodontal treatment resulted in significant improvement in the periodontal condition, and periodontal therapy had a beneficial effect on the signs and symptoms of RA, regardless of the medications used to treat this condition[68]. Additionally, anti-TNF-α therapy for active RA was highly safe and efficient in a small group of RA patients with coexistent collagen disease[69].

Conclusion

Although other targeted therapies and improved versions of existing drugs are being developed, we have already obtained vast knowledge about anti-TNF-α compounds in clinical practice. Many studies have addressed the efficacy, safety and continuation of anti-TNF-α agents in RA patients and revealed important information. These agents have beneficial effects on the progression of rheumatic diseases at the bone level[11] and lead to a substantial change in the treatment of RA. Treatment with anti-TNF-α drugs other than those recommended are also beneficial[8]. There are no significant differences in effectiveness between infliximab, etanercept and adalimumab[70]. However, differential clinical efficacy for these three agents has been demonstrated in several trials with different RA patient populations. Studies reported that non-responders to one of these compounds often positively respond to another, and TNF-α antagonists in combination with MTX have been
proven effective under certain conditions. Different mechanisms of action of these three compounds may partially explain these findings. Because different compounds and therapeutic strategies have different clinical effects, it is vitally important to determine how to stratify patients prognostically as a means of selecting the most effective anti-TNF treatment with the highest probability of success and lowest potential to produce side effects.

These compounds are beneficial for RA patients, but several side effects are elicited. Serious infections are frequent in daily practice\(^7^{[2]}\). Patients receiving anti-TNF-α drugs are more prone to experience adverse events, and those using infliximab and adalimumab have higher withdrawal rates\(^8^{[8]}\). In addition, incorrect therapeutic strategy may also decrease the efficacy of these compounds. For example, the use of infliximab and etanercept in combination with MTX may cause lower titers and lower response rates\(^7^{[2]}\). For patients with no previous resistance to MTX, the relative efficacy of anti-TNF-α drugs in combination with MTX is much lower compared with that of MTX alone. Etanercept and adalimumab are superior to placebo, but their effects as single agents are similar to that of MTX\(^8^{[8]}\). For elderly RA patients, there are significantly high numbers of adverse events, including frequent infections\(^7^{[2]}\).

In conclusion, the effects of anti-TNF-α agents in RA patients are complex. The proper selection of anti-TNF-α agents and the optimal therapeutic strategy should be investigated in long-term follow-up studies. We are still awaiting a complete set of clinical and biological criteria capable of classifying RA patients and predicting their responses to different treatments.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (grant No 30973543).

References

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358: 903–11.

2. Popa C, van Tits LJ, Barrera P, Lemmers HL, van den Hoogen FH, van Riel PL, et al. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis 2009; 68: 868–72.

3. Voulgaris PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA. Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med 2009; 117: 158–20.

4. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400–11.

5. Burmester GR, Mariette X, Montecucco C, Montecugudo-Saez I, Malaise M, Tzoufas AG, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007; 66: 732–9.

6. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443–50.

7. Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, Dinant H, et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis 2008; 67: 1139–44.

8. Alonso-Ruiz A, Pijoan JL, Ansuatregui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systemic review and meta-analysis of efficacy and safety. BMC Musculoskelet Disord 2008; 9: 52.

9. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007; 56: 13–20.

10. Ferraro-Peyret C, Tebib JG, Bienvenu J, Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Rheum 2004; 6: R535–43.

11. Bacquet-Deschryver H, Jouen F, Quillard M, Menard JF, Goeb V, Lequerre T, et al. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol 2008; 28: 445–55.

12. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006; 10: iii–iv, x–xiii, 1–229.

13. Jarry JL, Coombs RB, De Meafo FG, Rattray AH, Balaram R, Russell A. Projected patterns of compliance associated with Remicade (infliximab) and Enbrel (etanercept). J Rheumatol 2002; 29: 1564.

14. Musacchio E, Valvason C, Botiosos O, Ostuni F, Furlan A, Ramonda R, et al. The tumor necrosis factor-alpha-blocking agent infliximab inhibits interleukin 1 beta (IL-1beta) and IL-6 gene expression in human osteoblastic cells. J Rheumatol 2009; 36: 1575–9.

15. Pfirrmann CW, Furst DE, Weinblatt ME, Keystone EC, Moreland LW. Impact of concomitant methotrexate therapy on the radiographic progression of early rheumatoid arthritis: a two-year prospective study. Arthritis Rheum 2002; 46: 1435–42.

16. Bai J, Xiang W, Zhao H, Liu J, Wu C, Liu Q, et al. Projected patterns of compliance associated with Remicade (infliximab) and Enbrel (etanercept). J Rheumatol 2002; 29: 1564.

17. Musacchio E, Valvason C, Botiosos O, Ostuni F, Furlan A, Ramonda R, et al. The tumor necrosis factor-alpha-blocking agent infliximab inhibits interleukin 1 beta (IL-1beta) and IL-6 gene expression in human osteoblastic cells. J Rheumatol 2009; 36: 1575–9.

18. Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 1558–65.

19. Qureshi A, Errot A, Palacios C, Tomas C, Sanchez X, Barcelo P, et al. An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. PLoS One 2009; 4: e7556.

20. Trocmé C, Marotte H, Baillet A, Pallot-Prades B, Garin J, Grange L, et al. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1328–33.

21. Rau R. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 2002; 61 Suppl 2: ii70–3.

22. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003; 25: 1700–21.

23. Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF — antagonist therapy in...
clinical practice. *Rheumatology (Oxford)* 2007; 46: 1191–9.

21 St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. *Arthritis Rheum* 2004; 50: 3432–43.

22 Combe B, Codreanu C, Focco U, Gaubitz M, Geusens PP, Kvien TK, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. *Ann Rheum Dis* 2009; 68: 1146–52.

23 Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P. Long term safety of etanercept in elderly subjects with rheumatic diseases. *Ann Rheum Dis* 2006; 65: 379–84.

24 Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. *J Rheumatol* 2006; 33: 234–43.

25 Schiff MH, Yu EB, Weinblatt ME, Moreland LW, Genovese MC, White B, et al. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. *Drugs Aging* 2006; 23: 167–78.

26 Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. *Clin Exp Rheumatol* 2007; 25: 40–6.

27 Bendtzien K, Geborek P, Svensson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. *Arthritis Rheum* 2006; 54: 3782–9.

28 Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. *Arthritis Rheum* 2003; 48: 35–45.

29 van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. *Ann Rheum Dis* 2004; 63: 508–16.

30 Tang B, Rahman M, Waters HC, Callegari P. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. *Clin Ther* 2008; 30: 1375–84.

31 Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheum* 2006; 54: 26–37.

32 Levalampi T, Korpela M, Vuotteenaho K, Moliainen E. Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment. *Rheumatol Int* 2008; 28: 261–9.

33 van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. *Arthritis Rheum* 2006; 54: 1063–74.
four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381–90.

Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005; 52: 1020–30.

Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552–63.

Du Pan SM, Gabay C, Finckh A. A systematic review of infliximab in the treatment of early rheumatoid arthritis. Ther Clin Risk Manag 2007; 3: 905–11.

Weaver AL, Lautenheiser RL, Schiff MH, Gobofsky A, Perruquet JL, Luethkemeyer J, et al. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Curr Med Res Opin 2006; 22: 185–98.

van der Heijde D, Burmester G, Melo-Gomes J, Codreanu C, Martin Mola E, Pedersen R, et al. Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy. Ann Rheum Dis 2009; 68: 1113–16.

van der Heijde D, Burmester G, Melo-Gomes J, Codreanu C, Mola EM, Pedersen R, et al. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. Ann Rheum Dis 2008; 67: 182–8.

van Riel PL, Freundlich B, MacPeek D, Pedersen R, Foehl JR, Singh A. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Ann Rheum Dis 2008; 67: 1104–10.

Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675–81.

Iwamoto N KA, Fujikawa K, Aramaki T, Kawashiri SY, Tamai M, Arima K, et al. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. Mod Rheumatol 2009; 19: 488–92.

Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58: 964–75.

Keystone EC, Genovese MC, Klarpegoff L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor (alpha) given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009; 68: 789–96.

Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, et al. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. J Rheumatol 2009; 36: 1371–9.

Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009; 374: 210–21.

Oldfield V, Plosker GL. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and anklyosing spondylitis. BioDrugs 2009; 23: 125–35.

Nesbitt A FG, Bergin M, Stephens P, Stephens S, Foulkes R, Brown D, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007; 13: 1323–32.

Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtenk S, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68: 797–804.

Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68: 805–11.

Uģis F, Akman C, Kucukarsac S, Tufekci O. Anti-tumor necrosis factor-alpha therapy is associated with less frequent mood and anxiety disorders in patients with rheumatoid arthritis. Psychiatry Clin Neurosci 2009; 63: 50–5.

Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 2008; 8: 104–6.

Chuang E, Del Vecchio A, Smolinski S, Song XY, Sarisky RT. Bio-medicines to reduce inflammation but not viral load in chronic HCV—what's the sense? Trends Biotechnol 2004; 22: 517–23.

Ortiz P, Bissada NF, Palomo L, Han YW, Al-Zahrani MS, Panneerselvam A, et al. Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors. J Periodontol 2009; 80: 535–40.

Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results. Isr Med Assoc J 2008; 10: 277–81.

Arenerre Mendoza M, Manero Ruiz FJ, Carrera Lasfuentes P, Navarro Aznarez H, Pecondon Espanol A, Rabanaque Hernandez MJ. Tumour necrosis factor alpha antagonists in established rheumatoid arthritis: Effectiveness comparative study. Med Clin (Barc) 2010; 134: 665–70.

Salliot C, Gossec L, Ruysen-Witrand A, Luc M, Duclos M, Guignard S, et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 2007; 46: 327–34.

Breznitschek HP, Hofstetter T, Lee B, Haindl P, Graninger WB. Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate. Curr Opin Rheumatol 2008; 20: 295–9.

Filippini M, Bazzani C, Favalli EG, Marchesoni A, Atzeni F, Sarzi-Puttini P, et al. Efficacy and safety of anti-tumor necrosis factor in elderly patients with rheumatoid arthritis: An observational study. Clin Rev Allerg Immunol 2010; 38: 90–6.